ZEVONTABART
UNII BT8K2H7SXB

Substance Identification & Data

This profile provides standardized clinical and technical data for Zevontabart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) BT8K2H7SXB.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3060218-90-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

BT8K2H7SXB

CAS Registry Number

3060218-90-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

ZEVONTABART

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

13956

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Zevontabart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

ZEVONTABART

Common Names & Synonyms

IMMUNOGLOBULIN G1 (220-CYSTEINE,DE-C-TERMINAL LYSINE), ANTI-(HUMAN HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET) (HUMAN-MUS MUSCULUS MONOCLONAL Q397 .GAMMA.1-CHAIN), DISULFIDE WITH (206''-CYSTEINE) HUMAN-MUS MUSCULUS MONOCLONAL Q397 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS MET (MET PROTO-ONCOGENE, HEPATOCYTE GROWTH FACTOR (HGF) RECEPTOR, HGFR, SCATTER FACTOR (SF) RECEPTOR, HGF/SF RECEPTOR, RECEPTOR TYROSINE-PROTEIN KINASE C-MET, PAPILLARY RENAL CELL CARCINOMA 2, RCCP2)), HUMANIZED MONOCLONAL ANTIBODY (ZEVONTABA)RT

MONOCLONAL ANTIBODY; H-GAMMA1 HEAVY CHAIN HUMANIZED (1-442) (VH (HOMO SAPIENS IGHV1-2*06 (88.8%) -(IGHD) -IGHJ6*01 (85.7%), CDR-IMGT (8.8.8) (26-33.51-58.97-104)) (1-115) -HOMO SAPIENS IGHG1*03, G1M3, NG1M1 CH1 R120, CH3 E12, M14, 14-G1V96-1 HINGE C7, DEL8, DEL10 (CH1 R120 (212) (116-213), HINGE 1-7,9,11-15 K>C (220), T8>DEL, T10>DEL (214-226), CH2 (227-336), CH3 E12 (352), M14 (354) (337-441), CHS K2>DEL (442)) (116-442)), (218-215')-DISULFIDE WITH L-KAPPA LIGHT CHAIN HUMANIZED (1'-215') (V-KAPPA (HOMO SAPIENS IGKV1-39*01 (83.3%) -IGKJ4*01 (100%), CDR-IMGT (7.3.9) (27'-33'.51'-53'.90'-98')) (1'-108') -HOMO SAPIENS IGKC*01 (99.1%) KM3 A45.1, V101, 16-KCV93-1 C117 (C-KAPPA A45.1 (154'), V101 (192'), V117>C (206')) (109'-215')); DIMER (220-220'':222-222'':225-225'')-TRISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, GLYCOFORM ALFA

ZEVONTABART [INN]

Technical Codes

Q397

Q-397

External Clinical & Regulatory Resources

Previous UNIIBT8F8AD6WO

Next UNIIBT8LGQ9JLG